A study of TAK-861 in individuals with narcolepsy type 1
Résumé de l'étude
This is a double-blind study, meaning that neither the study participants nor the investigator knows which treatment each participant receives (TAK-861, in different doses or placebo). Placebo tablets, which contain no active ingredient, look exactly like the TAK-861 tablets. This ensures that participants do not know which treatment they are receiving. The use of a placebo is necessary to determine whether TAK-861 actually has an effect on the symptoms of participants with NT1. Participants will first be screened to ensure they meet the study participation criteria. Participants who meet the study criteria will then receive either TAK 861 or a placebo for 12 weeks. At the end of the study, participants will be invited to participate in an extension study in which all participants will receive TAK-861, allowing researchers to gather more information on the safety of the study treatment. Participants who choose not to participate in the extension study will be followed for 4 weeks after their last dose. What do the study visits include? Participants receive the investigational product or a placebo (a substance that resembles the investigational product but contains no active ingredients) and undergo various assessments and procedures as part of the study. Neither the participants nor the study staff know who receives the investigational product and who receives the placebo. Participants will have approximately 10 scheduled study visits over a period of 14 to 23 weeks. The duration of the study depends on the current narcolepsy medications (which must be discontinued before the study begins). At the end of the study, participants may have the opportunity to participate in a long-term extension study in which all participants receive the actual investigational product.
(BASEC)
Intervention étudiée
Participants are randomly assigned to groups, similar to drawing a stick. Some receive the investigational treatment (TAK-861), others a placebo, which is a substance without medical effect, often referred to as a "sugar pill." The treatment (TAK-861 or placebo) is administered over a period of 12 weeks.
(BASEC)
Maladie en cours d'investigation
Narcolepsy with cataplexy (Narcolepsy type 1)
(BASEC)
Study population: This study can include men and women who meet the following essential study criteria at the start of the study: ▪ They are 18 to 70 years old. ▪ They have been diagnosed with narcolepsy type 1. ▪ They must achieve the minimum score on the Epworth Sleepiness Scale. ▪ They must experience a minimum number of cataplexy attacks per week. ▪ They have tested positive for a specific group of genes that regulate the immune system, or they have a low orexin level in the cerebrospinal fluid. (BASEC)
Critères d'exclusion
Potential study participants cannot participate in the study if any of the following apply: • They have a condition (other than narcolepsy) that is associated with excessive daytime sleepiness. • They have had cancer within the last 5 years. • They have a history of certain brain disorders or a severe head injury. • They have a history of heart attack or certain other serious health issues. • They regularly go to sleep after midnight, work night shifts, or plan a trip during the study period that involves jet lag. (BASEC)
Lieu de l’étude
Berne, Lugano, Autre
(BASEC)
Aargau
(BASEC)
Sponsor
Sponsor: TAKEDA Sponsor’s representative in Switzerland :PPD Switzerland GmbH c/o Dufour Treuhand AG
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Prof. Dr. med. Ramin Khatami
+41 62 857 21 11
ramin.khatami@clutterbarmelweid.chCenter for Sleep Research and Sleep Medicine, Barmelweid, 5017 Clinic, Barmelweid AG, Switzerland
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
24.07.2024
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK 861 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1) (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible